Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

426
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
426
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

317
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
317

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Premature ventricular contraction-mediated ventricular fibrillation: Clinical characteristics, application of machine-learning algorithm, and outcomes of catheter ablation-A case series.

Heart rhythm O2·2026
Same author

A network meta-analysis of comparative effectiveness and safety of pulsed field, radiofrequency, and cryoballoon ablation for atrial fibrillation.

Heart rhythm O2·2026
Same author

Safety and Outcomes of Concomitant Left Atrial Appendage Occlusion and Atrial Fibrillation Ablation.

JACC. Advances·2026
Same author

Proper Use of the National Inpatient Sample Database to Analyze Safety of Cardiovascular Procedures.

Journal of the American Heart Association·2026
Same author

Anticoagulation alone vs anticoagulation plus antiplatelet therapy in atrial fibrillation with stable coronary disease: A meta-analysis of randomized trials.

Heart rhythm O2·2026
Same author

Safety and Outcomes of Intracardiac Versus Transesophageal Echocardiography for Left Atrial Appendage Closure in the Very Elderly: Propensity Score Matched Real-World Outcomes From a Large US Network.

Circulation. Arrhythmia and electrophysiology·2026

Related Experiment Video

Updated: Mar 2, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

Apixaban in patients with Atrial Fibrillation: A Systematic Review.

Abhishek Maan1, E Kevin Heist1, Amir Y Shaikh1

  • 1Cardiac Arrhythmia Service, Massachusetts General Hospital, 55 Fruit St. GRB 109, Boston, MA 02114.

Journal of Atrial Fibrillation
|May 13, 2017
PubMed
Summary

Atrial fibrillation (AF) increases stroke risk significantly. Apixaban, a novel oral anticoagulant, offers a new therapeutic option for stroke prevention in AF patients, addressing limitations of traditional therapies.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K
Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

20.3K

Related Experiment Videos

Last Updated: Mar 2, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K
Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

20.3K

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Atrial fibrillation (AF) is a prevalent cardiac arrhythmia, increasing stroke and embolism risk five-fold.
  • AF-related strokes are severe, necessitating effective primary prevention strategies.
  • Antithrombotic therapy is crucial for stroke prevention in AF patients.

Purpose of the Study:

  • To review the pharmacological properties of apixaban.
  • To evaluate clinical trial data on apixaban for stroke prevention in AF.
  • To discuss the future clinical potential of apixaban.

Main Methods:

  • Literature review of pharmacological data.
  • Analysis of results from clinical trials investigating apixaban.
  • Discussion of clinical practice implications.

Main Results:

  • Apixaban is a novel oral anticoagulant developed for stroke prevention in AF.
  • Clinical trials have investigated its efficacy and safety profile.
  • Apixaban presents an alternative to traditional anticoagulants like Vitamin K antagonists (VKAs).

Conclusions:

  • Apixaban offers a modern therapeutic option for stroke prevention in AF.
  • It addresses some limitations associated with VKAs, such as monitoring requirements.
  • Further evaluation of apixaban's role in clinical practice is warranted.